Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.
Founder Mark Harris and Gillian Hooker, VP of clinical development, explain why a more efficient Genetic Health Information Network is critical to the advancement of precision medicine.
The system being developed would enable clinical decision-making based on genetic information about cancer cells and will leverage Fronteo's AI engine called KIBIT.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.
The organizations will evaluate Owlstone's FAIMS technology as a valid method to screen patients who are inadequately prepared for a colonoscopy.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
The blood-based test is based on three serum biomarkers —matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1.
The collaborating researchers aim to develop a test kit that uses a minimum amount of electricity, and can still send information from some of the most remote regions of the world.
The firms said that the kit will employ microparticle biomarker technology to identify and monitor patients at high risk of coagulation complications.
The test will leverage Chembio's DPP technology platform to detect multiple diseases simultaneously.